For patients who have inflammatory bowel syndrome (IBS), the condition is literally a pain in the gut. Chronic -- or long-term -- abdominal pain is common, and there are currently no effective treatment options for this debilitating symptom. In a new study in ACS Pharmacology & Translational Science, researchers identify a new potential source of relief: a molecule derived from spider venom. In experiments with mice, they found that one dose could stop symptoms associated with IBS pain.
The sensation of pain originates in electrical signals carried from the body to the brain by cells called neurons. Tiny channels in the surfaces of neurons help them transmit these signals by allowing positively charged sodium ions to pass into the cell. There are numerous types of sodium channels, and some pain-killing drugs work by blocking them. However, existing treatments interfere with channels indiscriminately and can only be used briefly -- not for chronic pain. Stuart Brierley, Glenn King and colleagues wanted to find a way to selectively target the channels activated during chronic IBS pain.
The researchers focused on a particular sodium channel they suspected was responsible for chronic IBS pain. Then, to block it, they turned to the richest known source of molecules that alter the activity of sodium channels: spider venom. In the venom of a Peruvian tarantula, they discovered a molecule that they named Tsp1a, which had promising blocking activity. To test its potential as a treatment, the researchers used mice that had an IBS-related condition, and they monitored the mice during the experiment to detect a reflex associated with pain. A single Tsp1a treatment delivered into the mice's colons significantly reduced the occurrence of this reflex, indicating pain relief. What's more, Tsp1a appeared highly selective and did not interfere with other body functions, suggesting it could be used safely in humans. While Tsp1a shows promise as a potential treatment for chronic IBS pain, thorough studies of its activity in the body and the immune system's reaction to it will be critical, the researchers write.
The authors acknowledge funding from the Australian National Health and Medical Research Council, the Australian Research Council, the U.S. National Institutes of Health and The University of Queensland. Four of the authors are co-inventors on a U.S. patent application that covers the sequence, derivatives and methods of use for Tsp 1a.
The abstract that accompanies this paper is available here.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world's scientific knowledge. ACS' main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact firstname.lastname@example.org.